3M Company (MMM) - 2006 Annual Report (10-K) Summary
Business Context and Reporting Period
This filing covers the fiscal year ended December 31, 2006. 3M is a diversified global technology company operating in six segments: Industrial and Transportation, Health Care, Display and Graphics, Consumer and Office, Safety, Security and Protection Services, and Electro and Communications. The company employs approximately 75,333 people globally. A major strategic event in 2006 was the decision to divest its global branded pharmaceuticals business, with sales completed in December 2006 and January 2007.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Net Sales | $22,923 million | $21,167 million |
| Net Income | $3,851 million | $3,111 million |
| Diluted EPS | $5.06 | $3.98 |
| Operating Income | $5,696 million | $4,854 million |
| Operating Margin | 24.8% | 22.9% |
| Free Cash Flow (Operating) | $3,839 million | $4,204 million |
| Total Debt | $3,553 million | $2,381 million |
| Cash & Equivalents | $1,447 million | $1,072 million |
| Debt-to-Capital Ratio | 26% | 19% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.3% year-over-year, driven by core local-currency sales growth of 5.6% and acquisitions (notably CUNO in 2005 and Security Printing in 2006). All six business segments contributed to positive local-currency sales growth.
- Profitability Surge: Net income rose 23.8%. This was significantly boosted by a $1.074 billion pre-tax gain on the sale of the branded pharmaceuticals business. Excluding this gain and other items (restructuring, tax adjustments), underlying operating performance remained strong.
- Segment Performance:
- Health Care: Operating income jumped 65.6% primarily due to the gain on the pharmaceutical sale. Excluding the sale, the remaining Health Care businesses saw a 9.1% decline in operating income due to restructuring and R&D charges.
- Display and Graphics: Operating income declined 8.6% due to price declines in optical films and operational challenges with a new production line.
- Industrial and Transportation: Sales grew 9.9% and operating income grew 10.9%, led by adhesives, tapes, and the automotive aftermarket.
- Cost Pressures: Cost of sales increased 1.9 percentage points due to higher raw material costs (metals, oil-derived materials) and supply chain inefficiencies.
Guidance, Outlook, and Risks
- 2007 Outlook: Management expects earnings growth to be slowest in Q1 2007 due to restructuring costs and a strong Q1 2006 comparison. Earnings are expected to accelerate in the second half of 2007. Capital expenditures are projected to increase to $1.4–$1.5 billion in 2007.
- Pharmaceutical Divestiture Impact: The sale of the pharmaceutical business will negatively impact 2007 sales growth and operating income margins in the Health Care segment. 3M will retain a supply relationship with the buyers, generating approximately $100 million in annual revenue with lower profitability.
- Shareholder Returns: In February 2007, the Board authorized a $7 billion share repurchase program (2007–2009) and increased the quarterly dividend by 4.3% to $0.48 per share.
- Risks:
- Legal Proceedings: Significant exposure remains regarding respirator mask/asbestos litigation (approx. 17,700 pending claims) and environmental matters (PFOA/PFOS compounds). The company maintains reserves but notes outcomes are difficult to predict.
- Commodity Prices: Fluctuations in raw material costs (metals, oil) and foreign currency exchange rates (60%+ of revenue is international) pose ongoing risks.
Investor Verification Checklist
- Pharmaceutical Sale Proceeds: Verify the timing of cash receipt from the European pharmaceutical sale (completed Jan 2007) and its impact on Q1 2007 liquidity.
- Restructuring Costs: Monitor the execution of the $403 million restructuring plan, particularly the cash outflows expected in 2007 for severance and benefits.
- Asbestos Litigation Reserves: Review the adequacy of the $181 million liability reserve against the $380 million insurance receivable for respirator/asbestos claims, noting the uncertainty of future claim volumes and insurer solvency.
- Display Segment Turnaround: Assess whether the operational challenges in the optical film production line have been fully resolved to restore margins.
- Stock-Based Compensation: Note the increase in stock-based compensation expense in 2007 ($0.21/share vs $0.17/share in 2006) due to changes in vesting periods and a one-time "buyout" grant.